Deprenyl — Past and Future
Latest Publications

TOTAL DOCUMENTS

10

(FIVE YEARS 0)

H-INDEX

2

(FIVE YEARS 0)

Published By Springer Vienna

9783211828915, 9783709174944

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

New aspects of pathology in Parkinson’s disease with concomitant incipient Alzheimer’s disease

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_1 ◽

1996 ◽

pp. 1-6 ◽

Cited By ~ 2

Author(s):

H. Braak ◽

E. Braak ◽

D. Yilmazer ◽

R. A. I. Vos ◽

E. N. H. Jansen ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Parkinson’S Disease ◽

Alzheimer's Disease ◽

Parkinson's Disease

New horizons in molecular mechanisms underlying Parkinson’s disease and in our understanding of the neuroprotective effects of selegiline

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_2 ◽

1996 ◽

pp. 7-21

Author(s):

M. Gerlach ◽

H. Desser ◽

M. B. H. Youdim ◽

P. Riederer

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Molecular Mechanisms ◽

Neuroprotective Effects ◽

New Horizons

The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (−)-deprenyl research

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_4 ◽

1996 ◽

pp. 29-43

Author(s):

K. Magyar ◽

B. Szende ◽

J. Lengyel ◽

K. Tekes

Keyword(s):

Monoamine Oxidase ◽

Monoamine Oxidase Inhibitors

The clinical potential of Deprenyl in neurologic and psychiatric disorders

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_8 ◽

1996 ◽

pp. 85-93

Author(s):

W. Kuhn ◽

Th. Müller

Keyword(s):

Psychiatric Disorders ◽

Clinical Potential

Early diagnosis in Parkinson’s disease — limitation of biochemical markers and instrumental methods

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_3 ◽

1996 ◽

pp. 23-28

Author(s):

P. H. Kraus

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Early Diagnosis ◽

Biochemical Markers ◽

Instrumental Methods

Pharmacology and neuroprotective properties of rasagiline

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_9 ◽

1996 ◽

pp. 95-101 ◽

Cited By ~ 5

Author(s):

J. P. M. Finberg ◽

I. Lamensdorf ◽

J. W. Commissiong ◽

M. B. H. Youdim

Potential of neurotrophic factors in therapy of Parkinson’s disease

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_10 ◽

1996 ◽

pp. 103-112

Author(s):

J. C. Möller ◽

J. Sautter ◽

A. Kupsch

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Neurotrophic Factors

Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_6 ◽

1996 ◽

pp. 61-73 ◽

Cited By ~ 1

Author(s):

S. Yasar ◽

J. P. Goldberg ◽

S. R. Goldberg

Keyword(s):

Preclinical Research

(−)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_5 ◽

1996 ◽

pp. 45-59 ◽

Cited By ~ 2

Author(s):

W. G. Tatton ◽

J. S. Wadia ◽

W. Y. H. Ju ◽

R. M. E. Chalmers-Redman ◽

N. A. Tatton

Keyword(s):

Protein Synthesis ◽

Monoamine Oxidase ◽

Neuronal Apoptosis ◽

Neuronal Outgrowth

Deprenyl in the treatment of Parkinson’s disease: clinical effects and speculations on mechanism of action

Deprenyl — Past and Future ◽

10.1007/978-3-7091-7494-4_7 ◽

1996 ◽

pp. 75-84

Author(s):

C. W. Olanow

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Mechanism Of Action ◽

Clinical Effects